Everything below concerns cjc-1295. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
While reef-forming corals are almost entirely restricted to warm and shallow marine waters, other cnidarians can be found at great depths, in polar regions, and in freshwater. Cnidarians are a very ancient phylum, with fossils having been found in rocks formed about 580 million years ago during the Ediacaran period, preceding the Cambrian Explosion. Other fossils show that corals may have been present shortly before 490 million years ago and diversified a few million years later. Molecular clock analysis of mitochondrial genes suggests an even older age for the crown group of cnidarians, estimated around 741 million years ago, almost 200 million years before the Cambrian period, as well as before any fossils. Recent phylogenetic analyses support monophyly of cnidarians, as well as the position of cnidarians as the sister group of bilaterians.
== Development == Valve developed Half-Life 2 (2004) over six years using its new game engine, Source. Instead of beginning work on a full sequel, Valve decided to create a series of episodic sequels. The designer Robin Walker said the team had become comfortable with their tools, and wanted to capitalize on their experience instead of developing new technologies. Valve's president, Gabe Newell, said customers would be happier with a new Half-Life game delivered in a shorter time rather than waiting years for another "monolithic product". In April 2005, Valve announced the game under the working title Aftermath. The title Episode One was announced in February 2006. In May, Valve announced that Episode One would be the first in a trilogy of episodic games to be released over the following two years. Newell said he considered the trilogy the equivalent of Half-Life 3. According to Newell, whereas the original Half-Life (1998) saw the G-Man transform Freeman into his tool, and Half-Life 2 saw Freeman being used by G-Man, the episodes would see G-Man lose control. While the plots and dialogue of Half-Life and Half-Life 2 were written solely by Marc Laidlaw, the Half-Life 2 episodes were written by Laidlaw and the new employees Chet Faliszek and Erik Wolpaw. Valve's focus was character development, particularly that of Gordon's companion Alyx, who accompanies the player for most of Episode One. Walker said it was ironic that the player spends most of Half-Life 2 alone despite the themes of "characters and other people".
== Structure == Two identified transcript variants are expressed in several tissues and are evolutionarily conserved in fish and swine. One transcript, 1a, excises an intron and encodes the functional protein; this protein is the receptor for the ghrelin ligand and defines a neuroendocrine pathway for growth hormone release. The second transcript (1b) retains the intron and does not function as a receptor for ghrelin; however, it may function to attenuate activity of isoform 1a. GHS-R1a is a member of the G-protein-coupled receptor (GPCR) family. Previous studies have shown that GPCRs can form heterodimers, or functional receptor pairs with other types of G-protein coupled receptors (GPCRs). Various studies suggest that GHS-R1a specifically forms dimers with the following hormone and neurotransmitter receptors: somatostatin receptor 5, dopamine receptor type 2 (DRD2), melanocortin-3 receptor (MC3R), and serotonin receptor type 2C (5-HT2c receptor). See "Function" section below for details on the purported functions of these heterodimers.
Hahn's intention was still to work in industry. He received an offer of employment from Eugen Fischer, the director of Kalle & Co. (and the father of organic chemist Hans Fischer), but a condition of employment was that Hahn had to have lived in another country and have a reasonable command of another language. With this in mind, and to improve his knowledge of English, Hahn took up a post at University College London in 1904, working under Sir William Ramsay, who was known for having discovered the noble gases. Here Hahn worked on radiochemistry, at that time a very new field. In early 1905, in the course of his work with salts of radium, Hahn discovered a new substance he called radiothorium (thorium-228), which at that time was believed to be a new radioactive element. In fact, it was an isotope of the known element thorium; the concept of an isotope, along with the term, was coined in 1913 by the British chemist Frederick Soddy. Ramsay was enthusiastic when yet another new element was found in his institute, and he intended to announce the discovery in a correspondingly suitable way. In accordance with tradition this was done before the committee of the venerable Royal Society. At the session of the Royal Society on 16 March 1905 Ramsay communicated Hahn's discovery of radiothorium. The Daily Telegraph informed its readers:
Sources: en.wikipedia.org
=== Media and arts representation of sickle cell disease === Popular media and art have been important educational tools about sickle cell disease. Hertz Nazaire was a Haitian-American visual artist, writer, and advocate who lived with sickle cell disease and used his art to raise awareness, combat stigma, and champion better access to care. Representations of sickle cell disease in television shows include in the longrunning American medical drama ER (season 4 "Obstruction of Justice" and season 15 "Separation Anxiety" and "Dream Runner"), the 2024 British superhero series Supacell, in the 2024 period drama Lady in the Lake, and in the 2025 medical procedural drama The Pitt (episode "8:00 am"). Noah Wyle, who plays Dr. Michael "Robby" Robinavitch on The Pitt, has spoken about the importance of popular media representation of sickle cell and the impacts of racism on the quality of care patients receive. Sickle cell disease has also been featured in several movies including the 1973 Sydney Poitier classic, A Warm December, 1996 Nigerian drama Mortal Inheritance, Genie Award- winning 2008 Canadian drama Nurse.Fighter.Boy, the 2017 animated documentary Spilled Milk, the 2020 Nigerian drama Strain, the 2022 animated short The Park Bench, and the 2023 American sci-fi action film Transformers: Rise of the Beasts.
Nixon Gerrit Graham* (1970), film actor and songwriter Ed Harris* (1973), Academy Award-nominated actor and director, Apollo 13, The Truman Show, Pollock, Westworld Richard Thomas* (1973), star of The Waltons Robert Wisdom (1976), actor, Nashville, The Wire, Prison Break Mario Van Peebles (1978), star of Heartbreak Ridge and Sonny Spoon Jack Koenig (1981), actor Matt Salinger (1983), actor son of J.D. Salinger Robert Maschio (1988), actor on Scrubs Matthew Fox (1989), star of Party of Five and Lost Soterios Johnson (1990), radio journalist and WNYC host Schuyler Grant (1993), actress, great-niece of Katharine Hepburn Rachel DeWoskin (1994), actress and author, Foreign Babes in Beijing Jean Louisa Kelly (1994), star of Mr.
=== South Africa === In South Africa learnerships to qualify as a Phlebotomy Technician are offered by many public and private educational institutions as well as by private academies owned up by pathology laboratories (such as Ampath Laboratories, Lancet, PathCare) and healthcare service providers (such as Netcare, South African National Blood Service). Some of the larger retail pharmacy chains offering in-store clinical services (such as Clicks, Dis-Chem) also provide training for aspirant phlebotomists. Certification can be obtained from a number of examination and testing institutions. To work as a phlebotomist in South Africa, registration with the Health Professions Council of South Africa (HPCSA) is required.
=== Miscellaneous === Buprenorphine and dezocine are partial agonists of the MOR but antagonists of the KOR. Contrarily, eptazocine is an antagonist of the MOR but an agonist of the KOR; the same is also true for nalorphine and levallorphan. A variety of partial agonists or mixed agonists-antagonists of the MOR and KOR are also marketed, and include butorphanol, levorphanol, nalbuphine, pentazocine, and phenazocine. All of the aforementioned drugs may be described as opioid modulators instead of as pure antagonists. With the sole exception of nalorphine, all of the preceding are used as analgesics (by virtue of the fact that both MOR and KOR agonism independently confer pain relief). However, these opioid analgesics have atypical properties in comparison to the prototypical pure MOR full agonist opioid analgesics, such as less or no risk of respiratory depression for MOR partial agonists and antagonists, reduced or no euphoria, abuse potential, and dependence liability with MOR partial agonists/antagonists, and use- and dose-limiting side effects such as dysphoria and hallucinations with KOR agonists. In addition, by virtue of its KOR antagonism, buprenorphine (as buprenorphine/samidorphan (ALKS-5461) or buprenorphine/naltrexone to block its MOR agonism) is under investigation for the treatment of depression and cocaine dependence, as are other KOR antagonists such as aticaprant and, previously, JDTic and PF-4455242 (both discontinued due to toxicity concerns).
This was subsequently transferred to Innate Pharma in March 2020. On 10 December 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Lumoxiti, intended for the treatment of relapsed or refractory hairy cell leukemia after two prior systemic therapies including a purine nucleoside analog. The orphan designation for Lumoxiti for treatment of hairy cell leukaemia was also maintained. The applicant for this medicinal product is AstraZeneca AB. Moxetumomab pasudotox was approved for medical use in the European Union in February 2021. The EU marketing authorization was withdrawn in July 2021.
Sources: en.wikipedia.org
=== Molecular sieve === Molecular sieve is a material containing tiny pores of a precise and uniform size that is used as an absorbent for gases and liquids. They are metal alumino silicates which have a crystalline structure consisting of an assembly of tetrahedral. The tetrahedral are made up of 4 oxygen atoms which occupy the summits surrounding either 1 silicon atom or an aluminium atom placed in the center. Compensating cations (sodium, potassium) make the hole electrically neutral. The hole forms an assembly of small cells (or pores) of uniform and known size, in which a molecule of smaller size can be trapped by the phenomenon known as absorption. To ensure the dehydration of the fresh natural flowers the mixture of organic solvents is poured onto the hole until the level exceeds the level of the flowers by about 2 cm (0.79 in). The water molecules are progressively absorbed into the small cells or pores of the molecular sieve. The receptacle is closed hermetically for a few days. Once dried, the flower reabsorbs a little moisture of atmospheric origin, and this increases its suppleness and its plasticity. As molecular sieve relates to the long-term preservation and treatment of cut flowers for long duration, (i.e., continually maintaining their decorative properties), Vermont Flowers has been using this method of preserving flowers instead of the traditional silica gel more than 20 years ago. The advantage was a much more professional regeneration of the molecular sieves.
Internal waters: Waters landward of the baseline, over which the state has complete sovereignty: not even innocent passage is allowed without explicit permission from said state. Lakes and rivers are considered internal waters. Territorial sea: A state's territorial sea is a belt of coastal waters extending at most 22 kilometres from the baseline of a coastal state. If this overlaps with another state's territorial sea, the border is taken as the median line between the states' baselines, unless the states in question agree otherwise. A state can also choose to claim a smaller territorial sea. The territorial sea is regarded as the sovereign territory of the state. However, foreign ships (military and civilian) are allowed innocent passage through it, or transit passage for straits; this sovereignty also extends to the airspace over and seabed below. As a result of UNCLOS, states exercise a similar degree of control over their territorial sea as over land territory. They may thus utilise coast guard and naval patrols to enforce border control measures, provided they do not prevent innocent or transit passage. Contiguous zone: A state's contiguous zone is a band of water extending farther from the outer edge of the territorial sea to up to 44 kilometres (27 miles) from the baseline, within which a state can implement limited border control measures for the purpose of preventing or punishing "infringement of its customs, fiscal, immigration or sanitary laws and regulations within its territory or territorial sea".
peptide map A characteristic fractionation pattern produced by a particular polypeptide or protein when it is subjected to partial hydrolysis in vitro and the resulting peptide chains are separated by chromatography and/or electrophoresis.
==== Earthquakes ==== Some monitoring stations have reported that earthquakes are sometimes preceded by a spike in ultra-low-frequency (ULF) activity. A notable example of this occurred before the 1989 Loma Prieta earthquake in California, although a subsequent study indicated that this was little more than a sensor malfunction. On December 9, 2010, geoscientists announced that the DEMETER satellite observed a dramatic increase in ULF radio waves over Haiti in the month before the magnitude 7.0 Mw 2010 earthquake. Researchers are attempting to learn more about this correlation to determine whether this method can be used as part of an earthquake early warning system.
The 2024 New Year Honours are appointments by some of the 15 Commonwealth realms to various orders and honours to recognise and reward good works by citizens of those countries. The New Year Honours are awarded as part of the New Year celebrations at the start of January and those for 2024 were announced on 29 December 2023, on the same day as the 2022 Prime Minister's Resignation Honours. The recipients of honours are displayed as they were styled before their new honour and arranged by the country whose ministers advised Charles III on the appointments, then by the honour and by the honour's grade (i.e. Knight/Dame Grand Cross, Knight/Dame Commander, etc.), and then by divisions (i.e. Civil, Diplomatic, and Military), as appropriate. The BBC reported that it had already received press releases from some recipients before the honours list was published, contrary to the "longstanding practice of modest secrecy ahead of the announcement, even though award winners will have known for weeks".
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.